NasdaqGS - Nasdaq Real Time Price USD

BioNTech SE (BNTX)

94.10 -2.85 (-2.94%)
At close: 4:00 PM EDT
94.10 0.00 (0.00%)
After hours: 5:04 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
2,729,600.00
3,819,000.00
17,310,600.00
18,976,700.00
482,300.00
--
Cost of Revenue
562,900.00
599,800.00
2,995,000.00
2,911,500.00
59,300.00
--
Gross Profit
2,166,700.00
3,219,200.00
14,315,600.00
16,065,200.00
423,000.00
--
Operating Expense
2,424,100.00
2,315,000.00
2,011,800.00
1,138,100.00
505,400.00
--
Operating Income
-257,400.00
904,200.00
12,303,800.00
14,927,100.00
-82,400.00
--
Net Non Operating Interest Income Expense
471,800.00
349,700.00
29,600.00
-25,800.00
-3,500.00
--
Other Income Expense
--
-67,800.00
620,700.00
145,100.00
-59,900.00
--
Pretax Income
146,600.00
1,186,100.00
12,954,100.00
15,046,400.00
-145,800.00
--
Tax Provision
33,600.00
255,800.00
3,519,700.00
4,753,900.00
-161,000.00
--
Net Income Common Stockholders
113,000.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
--
Diluted NI Available to Com Stockholders
113,000.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
--
Basic EPS
0.49
3.87
38.78
42.18
0.06
--
Diluted EPS
0.47
3.83
37.77
39.63
0.06
--
Basic Average Shares
240,081.41
240,600.00
243,300.00
244,000.00
253,300.00
--
Diluted Average Shares
241,589.69
242,700.00
249,800.00
259,700.00
253,300.00
--
Total Operating Income as Reported
-471,200.00
690,400.00
12,642,700.00
15,283,800.00
-82,400.00
--
Rent Expense Supplemental
--
--
--
--
2,390.00
1,715.00
Total Expenses
2,987,000.00
2,914,800.00
5,006,800.00
4,049,600.00
564,700.00
--
Net Income from Continuing & Discontinued Operation
113,000.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
--
Normalized Income
165,260.57
983,455.20
8,982,530.40
10,193,251.60
57,130.00
--
Interest Income
455,400.00
357,600.00
48,500.00
1,500.00
1,600.00
--
Interest Expense
--
--
16,200.00
5,400.00
2,000.00
1,700.00
Net Interest Income
471,800.00
349,700.00
29,600.00
-25,800.00
-3,500.00
--
EBIT
-159,600.00
904,200.00
12,303,800.00
14,927,100.00
-143,800.00
--
EBITDA
30,700.00
1,087,600.00
12,427,100.00
15,002,300.00
-105,100.00
--
Reconciled Cost of Revenue
562,900.00
599,800.00
2,995,000.00
2,911,500.00
59,300.00
--
Reconciled Depreciation
190,300.00
183,400.00
123,300.00
75,200.00
38,700.00
--
Net Income from Continuing Operation Net Minority Interest
113,000.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
--
Total Unusual Items Excluding Goodwill
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
--
Total Unusual Items
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
--
Normalized EBITDA
98,500.00
1,155,400.00
11,806,400.00
14,857,200.00
-45,200.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-15,539.43
-14,644.80
168,830.40
45,851.60
-17,970.00
--
12/31/2019 - 10/10/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRNA Moderna, Inc.
153.20
-8.05%
 
NVAX Novavax, Inc.
15.52
+0.10%
 
CVAC CureVac N.V.
3.6700
-0.54%
 
MRUS Merus N.V.
54.87
-8.53%
 
CRSP CRISPR Therapeutics AG
54.84
-0.72%
 
INO Inovio Pharmaceuticals, Inc.
10.39
-5.55%
 
BDRX Biodexa Pharmaceuticals Plc
1.0800
+4.85%
 
VSTM Verastem, Inc.
4.0200
-2.43%
 
VRTX Vertex Pharmaceuticals Incorporated
446.88
-2.20%
 
IOVA Iovance Biotherapeutics, Inc.
9.70
-3.10%